Adrianne Clifford

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index312citations21works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(9), Cancer, Hypoxia, and Metabolism(6), Cancer-related gene regulation(4), Cancer Mechanisms and Therapy(4), Epigenetics and DNA Methylation(3)

Publications21 total

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
A novel approach to eliminate detection of contaminating Staphylococcal species introduced during clinical testing
PLoS ONE·2017· 3 citedOpen Access
Synthesis and Biological Evaluation of Pyrazolo[1,5-<i>a</i>]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors
ACS Medicinal Chemistry Letters·2014· 55 citedOpen Access
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
Neoplasia·2014· 90 citedOpen Access
Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2)
Bioorganic & Medicinal Chemistry Letters·2013· 49 cited
Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents
ACS Medicinal Chemistry Letters·2013· 13 citedOpen Access
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
Molecular Cancer Therapeutics·2013· 69 cited
Investigating the role of macrophages in tumor formation using a MaFIA mouse model
Oncology Reports·2013· 12 citedOpen Access
Synthesis and structure–activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 18 citedOpen Access
Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models
Cancer Research·2012· 1 cited
Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro.
Molecular Cancer Therapeutics·2011· 1 cited
Abstract B143: PKM2 metabolic activator slows lung cancer xenograft growth.
Molecular Cancer Therapeutics·2011
The dinucleotide prodrug of decitabine demonstrated increased in vivo efficacy due to enhanced drug delivery and stability
Cancer Research·2008
The decitabine-derived demethylating dinucleotide, S110 shows improved activity due to increased drug delivery and stability
Molecular Cancer Therapeutics·2007
Discovery and development of MP529, a new effective and selective inhibitor of Aurora A kinase.
Cancer Research·2007· 1 cited
page 1 of 2Next →

Frequent Co-authors

Michael V. McCullar(15), Jason M. Foulks(14), Steven B. Kanner(14), Anna V. Senina(11), K. Mark Parnell(10), Koc-Kan Ho(10), Rebecca N. Nix(9), Jeremy Bullough(9), Virgil McCarthy(9), David Vollmer(8), Jihua Liu(8), Michael Saunders(8), Marc O’Reilly(7), Bai Luo(7), Benjamin Brenning(6), Yong Xu(6), Scott Pearce(6), Kevin B. Wright(6), Bai Luo(5), Shannon Merx(5)